Low-grade Glioma Timing — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — The EORTC 22845 trial showed early RT improved PFS but NOT OS compared with deferred RT at progression
EORTC 22845 randomised patients with low-grade glioma to immediate vs deferred RT. While early RT improved PFS (5.3 vs 3.4 years), there was no OS difference (7.4 vs 7.2 years). This supports watchful waiting with serial MRI in selected patients (young, neurologically intact, maximal resection) to defer RT-associated neurocognitive toxicity. When treatment is indicated (symptoms, growth, transformation), RT + temozolomide (CATNON trial for astrocytomas) or RT + PCV (for oligodendrogliomas) is used.
Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer